Jackson Healthcare?, a family of highly specialized healthcare staffing, search and technology companies, announced that it has purchased the last manufacturing facility in the United States that is authorized to produce Amoxicillin and Amoxicillin Clavulanate, commonly known as Amoxil? and Augmentin?. With this acquisition, a critical piece of the nation's medical supply chain has been secured, reducing the country's growing dependence on foreign-produced, life-saving antibiotics.

Jackson Healthcare purchased the 360,000-square-foot, world-class antibiotic production facility located on more than 40 acres in Bristol, Tenn. on April 16, 2021. The acquisition has not only rescued the manufacturer from bankruptcy but put it under American ownership for the first time in its 43-year history.

Amoxicillin and Amoxicillin Clavulanate account for more than 30 percent of all antibiotics prescribed each year, and today, approximately one in 12 people in the U.S. are prescribed Amoxicillin on an annual basis. Given the widespread use and demand for these medications, restarting production in the Bristol manufacturing facility is significant, helping the U.S. build its supply of these essential antibiotics.